Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Mazieres J, et al. Among authors: bauer tm. Lung Cancer. 2022 Dec;174:146-156. doi: 10.1016/j.lungcan.2022.11.004. Epub 2022 Nov 7. Lung Cancer. 2022. PMID: 36410210 Free article. Clinical Trial.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. Among authors: bauer tm. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: bauer tm. J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. Online ahead of print. J Clin Oncol. 2024. PMID: 38819031
A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM. Liu G, et al. Among authors: bauer tm. Lung Cancer. 2024 May;191:107535. doi: 10.1016/j.lungcan.2024.107535. Epub 2024 Mar 15. Lung Cancer. 2024. PMID: 38554546 Free article. Review.
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler ME, Hütter-Krönke ML, Perotti A, Juif PE, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Bauer TM, et al. J Immunother Cancer. 2023 Nov 29;11(11):e007353. doi: 10.1136/jitc-2023-007353. J Immunother Cancer. 2023. PMID: 38030303 Free PMC article. Clinical Trial.
149 results